By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Qiagen will provide molecular diagnostics screening to women in Rwanda as part of a national cervical cancer prevention effort announced today.

As part of the initiative announced by Merck, Qiagen, and the government of Rwanda, Qiagen will provide screening for women between the ages of 35 and 45, and Merck will vaccinate girls between 12 and 15 years of age during the first three years of the program.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.